Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating reiterated by Oppenheimer in a report released on Tuesday.

Other research analysts have also recently issued reports about the stock. BidaskClub cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $191.00 price target (up from $170.00) on shares of Intercept Pharmaceuticals in a research report on Thursday, February 28th. Citigroup lifted their price target on shares of Intercept Pharmaceuticals from $106.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 21st. Royal Bank of Canada raised shares of Intercept Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Friday, March 1st. Finally, Zacks Investment Research cut shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $144.71.

Shares of ICPT stock opened at $111.97 on Tuesday. The company has a market cap of $3.37 billion, a price-to-earnings ratio of -10.31 and a beta of 1.62. The company has a debt-to-equity ratio of 19.41, a quick ratio of 4.22 and a current ratio of 4.22. Intercept Pharmaceuticals has a fifty-two week low of $58.03 and a fifty-two week high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). The business had revenue of $53.30 million for the quarter, compared to analyst estimates of $52.53 million. Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The company’s quarterly revenue was up 41.4% on a year-over-year basis. During the same period last year, the firm earned ($4.43) earnings per share. As a group, equities research analysts anticipate that Intercept Pharmaceuticals will post -9.1 earnings per share for the current fiscal year.

In other news, EVP Christian Weyer sold 333 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $103.16, for a total transaction of $34,352.28. Following the transaction, the executive vice president now directly owns 19,440 shares of the company’s stock, valued at $2,005,430.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Srinivas Akkaraju sold 23,438 shares of the business’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $128.78, for a total transaction of $3,018,345.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,558 shares of company stock worth $3,862,577. Corporate insiders own 4.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of ICPT. Geode Capital Management LLC increased its stake in Intercept Pharmaceuticals by 9.3% during the fourth quarter. Geode Capital Management LLC now owns 259,886 shares of the biopharmaceutical company’s stock valued at $26,193,000 after purchasing an additional 22,059 shares during the last quarter. Norges Bank bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $28,428,000. FMR LLC increased its stake in Intercept Pharmaceuticals by 0.3% during the fourth quarter. FMR LLC now owns 4,448,170 shares of the biopharmaceutical company’s stock valued at $448,331,000 after purchasing an additional 13,468 shares during the last quarter. Sofinnova Investments Inc. bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $5,491,000. Finally, Amalgamated Bank bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $322,000. 69.38% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Recommended Story: What is the Quick Ratio?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.